AstraZeneca Fights Damages In Drug Pricing Suit

Law360, New York (August 7, 2007, 12:00 AM EDT) -- On the heels of a similar bid by Warrick Pharmaceuticals Corp., AstraZeneca Pharmaceuticals LP has rejected a request that it shell out treble damages to two classes in the average wholesale price litigation, arguing that such a remedy is unwarranted.

AstraZeneca said in court documents filed Monday that the court’s findings did not support a conclusion that the drug giant had acted with malice or with the level of callousness necessary to justify the extraordinary remedy of treble damages.

The plaintiffs revealed their final damages calculations...
To view the full article, register now.